Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients

Growth and differentiation factor 15 (GDF15) is a significant player in cellular stress and energy homeostasis. GDF15 is elevated in cancer cachexia, chemotherapy-induced anorexia, hyperemesis gravidarum, and mitochondrial disorders. Here we analyze GDF15 in anorexia nervosa (AN), a psychiatric disorder characterized by low weight and persistent restriction of food intake. While no significant difference in plasma GDF15 concentration was seen across the three included groups; active AN, recovered AN, and healthy controls, a subgroup of study participants with high GDF15 plasma was noted to a significantly higher extent in the AN groups. Sparse partial least squares discriminant analysis (sPLS-DA) identified six markers related to inflammatory processes or cellular stress from a set of 74 markers that distinguished AN with high GDF15 from the rest, with fibroblast growth factor 21 (FGF21) being the most important contributor. Moreover, FGF21 plasma concentration was significantly higher in the group with high GDF15, suggesting an involvement of mitochondrial dysfunction. In fact, mitochondrial polygenic risk score (PRS) was significantly associated with AN risk in a large AN case-control cohort. In line with this, we also report elevated liver expression of GDF15 in the anx/anx mouse displaying anorexia associated with mitochondrial dysfunction. We conclude that mitochondrial dysfunction should be further explored in AN. Clinical trials of GDF15 immunoneutralization in patients with AN and high levels of GDF15 are worthy of consideration.

Authors

Institutions

Publication Details

Journal
Translational Psychiatry
Published
2025-06-25
DOI
https://doi.org/10.1038/s41398-025-03425-0
Citations
3
Primary Topic
GDF15 and Related Biomarkers
Type
article
Field-Weighted Citation Impact
5.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients

Cynthia Marie Bulik, Zeynep Yılmaz, Vincent Millischer, Stephen O’Rahilly et al.
3 citations
Translational Psychiatry
GDF15 and Related Biomarkers
5.00
article

Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients

Cynthia Marie Bulik, Zeynep Yılmaz, Vincent Millischer, Stephen O’Rahilly, Mikael Landén, Ruyue Zhang, Miranda Stiernborg, Ida Nilsson, Vanessa F. Gonçalves, Catharina Lavebratt, Jingjing Xu, Claire Tume, Peter Barker, Sara Mehdinia
article en
3 citations

Abstract

Growth and differentiation factor 15 (GDF15) is a significant player in cellular stress and energy homeostasis. GDF15 is elevated in cancer cachexia, chemotherapy-induced anorexia, hyperemesis gravidarum, and mitochondrial disorders. Here we analyze GDF15 in anorexia nervosa (AN), a psychiatric disorder characterized by low weight and persistent restriction of food intake. While no significant difference in plasma GDF15 concentration was seen across the three included groups; active AN, recovered AN, and healthy controls, a subgroup of study participants with high GDF15 plasma was noted to a significantly higher extent in the AN groups. Sparse partial least squares discriminant analysis (sPLS-DA) identified six markers related to inflammatory processes or cellular stress from a set of 74 markers that distinguished AN with high GDF15 from the rest, with fibroblast growth factor 21 (FGF21) being the most important contributor. Moreover, FGF21 plasma concentration was significantly higher in the group with high GDF15, suggesting an involvement of mitochondrial dysfunction. In fact, mitochondrial polygenic risk score (PRS) was significantly associated with AN risk in a large AN case-control cohort. In line with this, we also report elevated liver expression of GDF15 in the anx/anx mouse displaying anorexia associated with mitochondrial dysfunction. We conclude that mitochondrial dysfunction should be further explored in AN. Clinical trials of GDF15 immunoneutralization in patients with AN and high levels of GDF15 are worthy of consideration.

Translational PsychiatryVol. 15(1)
University of North Carolina at Chapel Hill (US), Karolinska University Hospital (SE), Centre for Addiction and Mental Health (CA), University of Toronto (CA), Aarhus University (DK), Cambridge University Hospitals NHS Foundation Trust (GB), Karolinska Institutet (SE), Comprehensive Cancer Center Vienna (AT), Wellcome/MRC Institute of Metabolic Science (GB), MRC Epidemiology Unit (GB), Medical University of Vienna (AT), University of Gothenburg (SE)
Lundbeckfonden, Hjärnfonden, Karolinska Institutet, Vetenskapsrådet, National Institute of Mental Health
Reduced inequalities
Openalex Percentile: Top 5%
GDF15 and Related Biomarkers
5.00
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.